Auditors found that Toledo’s psoriasis unit met 33 basic indicators and 15 excellence indicators under the AEDV’s Cuderma programme. The review also examined patient education, follow-up and cooperation between medical teams.
Auditors counted 33 basic indicators and 15 excellence indicators at the Unidad de Psoriasis of the Complejo Hospitalario Universitario de Toledo. The figures put the unit above the threshold for the highest Cuderma level, known as Excelente. That level requires at least 28 basic indicators and 12 excellence indicators.
The certification comes from the Academia Española de Dermatología y Venereología, or AEDV. It recognises care that combines treatment with patient education and a role for patients in health decisions.
The AEDV is an active professional reference point for dermatology in Spain, but that institutional context does not by itself replace confirmation of Toledo’s specific Cuderma result.
This was not a broad review. The Cuderma programme checks 53 quality criteria across resources, clinical procedures and patient outcomes. Auditors visit the site, review medical records and examine diagnosis, treatment and follow-up. They also check available resources and staffing.
The 53 criteria fall into three groups. Eight cover structure and human resources. Another 38 look at clinical processes, including diagnosis, treatment and monitoring. The final seven measure healthcare outcomes.
The numbers matter.
Cristina Pérez, director general of Asistencia Sanitaria, led the ceremony where the award was presented. Vanesa Aguilar, deputy managing director of the hospital, also attended. So did Blas Gómez, head of Dermatology; Pablo de la Cueva, secretary general of the AEDV; Antonio Manfredi, president of Acción Psoriasis; and Rita Bau, director of Institutional Relations at AbbVie. The Junta reported the event in an official note.
For a complete independent record of the distinction, the relevant verification trail includes an AEDV release, a publication from the Junta de Castilla-La Mancha or its health department, and, if applicable, a statement from Acción Psoriasis. The available search context did not independently locate a separate primary confirmation specifically documenting the Toledo award.
Psoriasis is a chronic inflammatory disease. Its effects can reach beyond the skin. Elena Martínez, the dermatologist responsible for the service, pointed to possible cardiovascular and metabolic comorbidities. She also cited psoriatic arthritis in a significant proportion of patients.
Since 2019, the unit has provided specialised and individualised care for people with moderate-to-severe or complex forms of the disease. Doctors choose treatment according to each patient’s characteristics and needs. They also keep patients under close review.
A specialised nursing consultation supports that work. Nurses educate patients and help with treatment adherence. The dermatology team works with Rheumatology as well. Together, they look for early signs of psoriatic arthritis and arrange joint assessments when needed.
The structure is designed to address the disease as a whole. It does not focus only on visible skin lesions.
Psoriasis treatment has also changed as researchers have learned more about the immune mechanisms behind the disease. The stated aim is broader control, fewer complications and a better quality of life.
That patient-centred focus contrasts with the housing pressures described in an earlier breakdown. The practical principle is similar: measure outcomes instead of relying on broad claims.
For patients in Toledo, the certification does not announce a new medicine or a new rule. Its meaning is practical. The unit has met a demanding set of standards across the full care pathway.
Dermatology, nursing support and cooperation with Rheumatology give the service a more structured approach. The assessment also shows how the unit follows patients over time. This is a documented review of chronic disease care, not only a mark of prestige.
